Clinical Trial Update: Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the pharmacokinetics and safety of TIN816 in patients with sepsis-associated acute kidney injury has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Sepsis

Drugs mentioned

• TIN816

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Kidney Injury Due to Sepsis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-01